ZANRÈ, VALENTINA
 Distribuzione geografica
Continente #
NA - Nord America 53
EU - Europa 41
AS - Asia 16
OC - Oceania 1
Totale 111
Nazione #
US - Stati Uniti d'America 53
IT - Italia 9
CN - Cina 7
FR - Francia 6
IE - Irlanda 6
SE - Svezia 6
KR - Corea 4
RU - Federazione Russa 4
DE - Germania 3
TW - Taiwan 3
SG - Singapore 2
SK - Slovacchia (Repubblica Slovacca) 2
AU - Australia 1
BE - Belgio 1
CH - Svizzera 1
FI - Finlandia 1
GB - Regno Unito 1
GR - Grecia 1
Totale 111
Città #
Chandler 13
Dublin 6
Bologna 5
Beijing 4
Seoul 4
Wilmington 4
Ashburn 3
Sindelfingen 3
Taichung 3
Lawrence 2
Michalovce 2
New York 2
Princeton 2
Seattle 2
Singapore 2
Athens 1
Boardman 1
Brussels 1
Chions 1
Edinburgh 1
Lappeenranta 1
Melbourne 1
Sant'Ambrogio di Valpolicella 1
Stockholm 1
Tombolo 1
Verona 1
Zurich 1
Totale 69
Nome #
Salviolone from Salvia miltiorrhiza roots impairs cell cycle progression, colony formation, and metalloproteinase-2 activity in a375 melanoma cells: involvement of P21(Cip1/Waf1) expression and STAT3 phosphorylation 50
Upregulation of miR-34a-5p, miR-20a-3p and miR-29a-3p by onconase in A375 melanoma cells correlates with the downregulation of specific onco-proteins 39
Hyperforin enhances heme oxygenase-1 expression triggering lipid peroxidation in BRAF-mutated melanoma cells and hampers the expression of pro-metastatic markers 16
Hyperforin elicits cytostatic/cytotoxic activity in human melanoma cell lines, inhibiting pro-survival NF-κB, STAT3, AP1 transcription factors and the expression of functional proteins involved in mitochondrial and cytosolic metabolism 13
Lamivudine, Doravirine, and Cabotegravir downregulate the expression of Human Endogenous Retroviruses (HERVs), inhibit cell growth, and reduce invasive capability in melanoma cell lines 2
Totale 120
Categoria #
all - tutte 742
article - articoli 742
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.484


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202220 0 0 0 0 0 0 0 12 4 0 0 4
2022/202346 2 3 5 7 2 10 1 3 9 0 2 2
2023/202451 3 5 5 5 6 8 2 5 1 9 1 1
2024/20253 3 0 0 0 0 0 0 0 0 0 0 0
Totale 120